The assay was shown to have a simpler workflow and was able to detect mosaicism, with only a slight decrease in sensitivity compared to a lab-developed test.
Using large-scale GWAS data, researchers saw shared genetic contributors for ALS and frontotemporal dementia, as well as ALS and progressive supranuclear palsy.
Speakers at HudsonAlpha's Genomic Medicine Conference said while sequencing results sometimes result in a diagnosis and change in care, they often have no consequence.
Based on their genome-wide association study, investigators argued that the dementia condition is not simply an extension of Alzheimer's or Parkinson's disease.
Researchers saw partial overlap between variants influencing age-related methylation and neuronal patterns and those implicated in other traits or diseases.
The companies said they aim to discover next-generation tests that will enable early diagnosis of dementia, as well as treatment selection and monitoring.
NEW YORK (GenomeWeb) – The Medical Research Council on Thursday announced a £16 million ($27 million) research project into dementia that includes the development of new biomarkers for identifying those at risk for developing the condition and patients who may be candidates for new drug trials.
The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.
